Heterocyclic Amide Kinase Inhibitors Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective inhibitors of protein kinases to treat or prevent disease states associated with abnormal cell proliferation, requiring compounds with high affinity and selectivity for target kinases such as CHK1, CHK2, VEGF-R2, Pim-1, PDK-1, CDKs, and CDK/cyclin complexes, as well as receptor and non-receptor tyrosine kinases.
Innovation Solution
Development of a novel class of heterocyclic amide compounds that function as protein kinase inhibitors, which can be used in pharmaceutical compositions to treat proliferative diseases, inflammation, arthritis, neurological disorders, cardiovascular diseases, and viral or fungal infections by targeting specific protein kinases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CDK inhibitors are used, then cell proliferation can be controlled, but selectivity among different kinase targets is insufficient
Solution Approach 1:
The patent applies local quality by designing specific molecular regions in the heterocyclic amide compounds that interact with particular kinase active sites. The compounds contain functional groups (such as amide bonds, heterocyclic rings) positioned to form specific hydrogen bonds and hydrophobic interactions with residues in the ATP-binding pocket of target kinases like CDK2, CHK1, and VEGF-R2, thereby achieving selectivity for specific kinase isoforms while maintaining broad kinase target coverage.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the heterocyclic amide core (such as substituent types, ring positions, stereochemistry) to optimize binding affinity and selectivity for different kinase targets. By changing molecular weight, logP, and specific functional group positions, the compounds achieve differential inhibition profiles across kinase families, resolving the contradiction between selectivity and versatility.
2Adaptability or versatility
If broad-spectrum kinase inhibitors are developed, then multiple disease targets can be addressed, but specificity for individual kinase isoforms decreases
Solution Approach 1:
The patent applies segmentation by dividing the kinase target family into distinct groups (CDKs, CHKs, VEGF-R, Pim kinases) and designing compound series with specific structural features optimized for each group. The heterocyclic amide core provides a platform for attaching different substituent patterns that selectively engage with isoform-specific residues, enabling broad disease target coverage while maintaining isoform specificity through modular structural design.
3Reliability
If high-affinity kinase binders are designed, then inhibitory potency increases, but drug metabolism and stability may be compromised
Solution Approach 1:
The patent applies this principle by incorporating metabolically labile linkers or prodrug moieties into the heterocyclic amide structure that can be cleaved by cellular esterases or other enzymes to release the active inhibitor. This allows the parent compound to have high potency but controlled metabolic stability, with the active form being generated in situ at the target site, thereby balancing inhibitory potency with appropriate metabolic profile.
Data Source
AI summary
The present invention relates to novel heterocyclic amide compounds of Formula I: as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are compositions comprising said compounds, and methods for using said compoundsfor treating or preventing a proliferative disease, an anti-proliferative disorder, inflammation, arthritis, a neurological or neurodegenerative disease, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease or a fungal disease.